Founded in 2015, Oncorus is focused on transforming cancer treatment through viral immunotherapies. Using its HSV Platform and Synthetic viral RNA (vRNA) Immunotherapy Platform, the company is developing intratumorally and intravenously administered product candidates that selectively attack and kill tumor cells while stimulating multiple arms of the immune system. Oncorus is also committed to corporate philanthropy, pledging to donate a portion of product sales to fund cancer research and support cancer care in developing countries.